Compare MasterCard Inc (MA) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs Sanofi SA — how do they compare? MasterCard Inc trades at $542.4 (market cap $483.71B), while Sanofi SA trades at $44.07 (market cap $104.83B). The key difference: MasterCard Inc is far larger — about 4.6× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| MA | SNY | |
|---|---|---|
Market Cap | $483.71B | $104.83B |
Volume | 4,635,698 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $598.96 | $52.34 |
52-Week Low | $471.55 | $41.33 |
Enterprise Value | $494.45B | $121.32B |
Dividend Yield | 0.64% | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $545.00, up 0.26% today, with strong technical support at $540 and resistance at $547. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $4.60 exceeding expectations of $4.41. Revenue grew to $32.79B in 2025, and net income margin remains high at 45.88%. Analysts maintain a bullish consensus with a $634.27 price target, citing momentum in digital payments and AI integration.
Outlook remains positive given consistent earnings outperformance and strategic initiatives in AI and financial inclusion. Key risks include competitive disruption from stablecoins and elevated valuation multiples. Institutional ownership trends show continued accumulation, supporting the bullish sentiment. The stock presents a growth opportunity but requires monitoring of payment industry evolution and valuation sustainability.
SNY trades at $43.97, down 1.55% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings of $1.10 per share, beating expectations, and maintains robust profitability with a 71.92% gross margin. Recent FDA approval for Sarclisa's subcutaneous formulation and expanded AI research collaboration with Aqemia highlight ongoing innovation. Cash flow from operations remains healthy at $10.75 billion for 2025, though net cash flow is minimal at $49 million.
SNY presents a balanced investment case with solid fundamentals and analyst support (44% buy ratings), but faces risks from EU antitrust probes and patent expiration concerns for key drug Dupixent. Valuation metrics appear reasonable with P/E of 19.81 and P/B of 1.29. The stock's outlook depends on successful drug pipeline execution and navigating regulatory challenges, with current price levels offering stability near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
